Show simple item record

Alpha-2-interferon/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I-II trial.

dc.contributor.authorCooper, M R
dc.contributor.authorFefer, A
dc.contributor.authorThompson, J
dc.contributor.authorCase, D C
dc.contributor.authorKempf, R
dc.contributor.authorSacher, R
dc.contributor.authorNeefe, J
dc.contributor.authorBickers, J
dc.contributor.authorScarffe, J Howard
dc.contributor.authorSpiegel, R
dc.date.accessioned2010-11-09T17:03:51Z
dc.date.available2010-11-09T17:03:51Z
dc.date.issued1986-04
dc.identifier.citationAlpha-2-interferon/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I-II trial. 1986, 70 (4):473-6 Cancer Treat Repen
dc.identifier.issn0361-5960
dc.identifier.pmid3698041
dc.identifier.urihttp://hdl.handle.net/10541/115188
dc.description.abstractAlpha-2-interferon (IFN) has demonstrable activity in advanced, relapsing, or refractory multiple myeloma. Because of the in vitro synergism between the IFNs and cytotoxic agents, we conducted a trial of 30 previously untreated patients with multiple myeloma utilizing various doses of alpha-2-IFN in combination with standard oral doses of melphalan and prednisone. The combination was well-tolerated without unusual or unexpected toxic effects. The limiting toxicity included dose-related myelosuppression, and alpha-2-IFN induced flu-like symptoms and fatigue. Response was seen in at least as many patients as would be expected with melphalan and prednisone alone. The maximal tolerated dose for a phase II-III trial was 5.0 X 10(6) IU/m2 of alpha-2-IFN in combination with standard doses of melphalan and prednisone. Future trials should utilize this dose of alpha-2-IFN with dose de-escalation according to tolerance.
dc.language.isoenen
dc.subjectAnticancerous Combined Chemotherapy Protocolsen
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshDose-Response Relationship, Drug
dc.subject.meshDrug Evaluation
dc.subject.meshFemale
dc.subject.meshHeart Diseases
dc.subject.meshHumans
dc.subject.meshInterferon Type I
dc.subject.meshLeukocyte Count
dc.subject.meshMale
dc.subject.meshMelphalan
dc.subject.meshMiddle Aged
dc.subject.meshMultiple Myeloma
dc.subject.meshPlatelet Count
dc.subject.meshPrednisone
dc.titleAlpha-2-interferon/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I-II trial.en
dc.typeArticleen
dc.identifier.journalCancer Treatment Reportsen
html.description.abstractAlpha-2-interferon (IFN) has demonstrable activity in advanced, relapsing, or refractory multiple myeloma. Because of the in vitro synergism between the IFNs and cytotoxic agents, we conducted a trial of 30 previously untreated patients with multiple myeloma utilizing various doses of alpha-2-IFN in combination with standard oral doses of melphalan and prednisone. The combination was well-tolerated without unusual or unexpected toxic effects. The limiting toxicity included dose-related myelosuppression, and alpha-2-IFN induced flu-like symptoms and fatigue. Response was seen in at least as many patients as would be expected with melphalan and prednisone alone. The maximal tolerated dose for a phase II-III trial was 5.0 X 10(6) IU/m2 of alpha-2-IFN in combination with standard doses of melphalan and prednisone. Future trials should utilize this dose of alpha-2-IFN with dose de-escalation according to tolerance.


This item appears in the following Collection(s)

Show simple item record